Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck stock declined 10% from $90 levels in the beginning of this year to $80 levels as of April 22, compared to a 13% decline for the broader S&P 500. While Merck’s stock has marginally outperformed the broader markets, we believe there is over 20% upside potential from the current levels.

Despite Outperforming The Broader Markets, Merck Appears To Be Oversold At $80

Coca-Cola

Mastercard

Wednesday's big stock charts feature names that are preparing to meet with their significant support lines.
The post 3 Big Stock Charts for Wednesday: Coca-Cola, Mastercard, and Merck appeared first on InvestorPlace.

3 Big Stock Charts for Wednesday: Coca-Cola, Mastercard, and Merck

- Ongoing Phase 1 dose escalation and expansion study with CUE-101 as a monotherapy in post first-line recurrent/metastatic HNSCC patients to be amended to include combination of CUE-101 with standard of care KEYTRUDA as first-line therapy  - Preliminary data  from early patient cohorts in the current ongoing CUE-101 monotherapy Phase 1 trial in  post first-line recurrent/metastatic HNSCC patients  demonstrates tolerability and drug exposure, and provides confidence for drug activity consistent with projections based on preclinical data   - Recent publication in Clinical Cancer Research includes supporting preclinical data for CUE-101 demonstrating anti-tumor efficacy as monotherapy and in combination with anti-PD-1 treatment

Cue Biopharma Announces Clinical Trial Collaboration Agreement with Merck to Evaluate CUE-101 in Combination with KEYTRUDA® (pembrolizumab) as First-line Treatment For HPV+ Recurrent/Metastatic Head and Neck Cancer

Merck (MRK) closed the most recent trading day at $82.07, moving -0.93% from the previous trading session.

Merck (MRK) Stock Moves -0.93%: What You Should Know

Merck: What Makes This Big Pharma Tick In April 2020

AbbVie

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials.

Big Pharma Short Sellers Focus on a Couple of Favorites

Merck's (MRK) sBLA seeking approval of Keytruda for advanced solid tumors, based on biomarker, regardless of tumor type, gets FDA's priority review.

Merck's Keytruda Gets FDA's Priority Review for Solid Tumors

AstraZeneca

Johnson & Johnson

Eli Lilly

Novartis

Pfizer

Large-Cap Pharma Stocks to Benefit in Post-Pandemic Market

Amgen

Bristol-Myers

Gilead Sciences

Sanofi

Track the latest trends and leading stocks in the biotech and pharmaceutical industries.

Biotech Stocks To Watch And Pharma Industry News

Merck stock advanced 19% in all of 2019. Meanwhile shares of other pharmaceutical companies grabbed smaller, single-digit percentage gains.

Is Merck Stock A Buy As Coronavirus Worries Shake Up Pharma Stocks?

An approval would give the immunotherapy another big leg up on Bristol Myers Squibb's similar treatment Opdivo.

Merck's Keytruda Receives Priority Review for a Key Indication

IDACORP

Alliant Energy

Value investors may be interested in these stocks for the following reasons:

3 Opportunities for the Value Investor

Merck (MRK) closed at $76.25 in the latest trading session, marking a -0.81% move from the prior day.

Merck (MRK) Stock Moves -0.81%: What You Should Know

Cintas Corp

Dolby Laboratories

Domino's Pizza

W.W. Grainger

Home Depot

Humana

New Linde PLC

Microsoft

Roper Technologies

Sherwin-Williams

T. Rowe Price Group

UnitedHealth Group

Visa

The longest bull market in history has blown up in spectacular fashion, thanks to the coronavirus pandemic that has shut economic activity all around the world.

15 Super-Safe Dividend Stocks to Buy Now

Merck's Keytruda Update, And Other News: The Good, Bad And Ugly Of Biopharma

The pharma giants want to help any way they can, and that means letting their thousands of medical professionals go where they are most urgently needed.

Pfizer, Merck, and Eli Lilly Will Pay Their Doctors to Get Back to Treating Patients During the COVID-19 Pandemic

While the outlook for both companies remains strong, as both the companies have a strong pipeline and existing drugs portfolio to drive revenue growth, we believe Merck could be a better bet in the current environment.

Sell Pfizer To Buy Merck?

Mylan

Several pharma & biotech companies announce their plan to fight coronavirus pandemic and state anticipated unfavorable impact of the outbreak on their business.

Pharma, Biotech Players Step Up Efforts Against Coronavirus

Keytruda is to Merck (NYSE: MRK) , the way iPhone is to Apple. From nothing, it garnered >$11 billion in sales over the last 5 years, and it is now a leading oncology drug.

Can Merck’s Keytruda Be Worth $200 Billion?

Merck (NYSE: MRK) revenue grew from $39.8 billion in 2016 to $46.8 billion in 2019, and it is estimated to top $51.5 billion in 2020, primarily driven by its oncology drug, Keytruda, according to our estimates. The company’s oncology drugs will account for 32% of the company’s total sales in 2020.

How Merck Gets To $51 Billion: Oncology or Vaccines?

Merck (NYSE: MRK) could see a 35% upside from the current levels, based on our price estimate of $96, which is based on expected 2020 earnings of $5.85 on an adjusted basis, and a price to earnings multiple of 16.4x. Merck’s stock has seen a 15% drop since February 1 (through March 18).

35% Upside For Merck’s Stock?

Keytruda, Supporting Cast, And Spin-Off Makes Merck A Buy

"Right now, we have the power as citizens to .... slow the spread of this virus," Merck CEO Kenneth Frazier told CNBC.

Merck CEO calls on all Americans to take coronavirus precautions so the US doesn't turn into Italy

Merck's (MRK) two phase III studies on gefapixant (MK-7264) for the treatment of refractory or unexplained chronic cough meet the primary efficacy endpoints.

Merck's Chronic Cough Candidate Achieves Goals in Phase III

Merck's Gefapixant could become the first FDA approved drug for chronic cough.

News for Merck Stock (MRK)